Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GILD Gilead Sciences	$111.79 +0.6%	$105.48	$62.07 ▼ $119.96	$139.22B	0.21	7.29 million shs	7.84 million shs
HUM Humana	$263.95 -2.4%	$270.14	$213.31 ▼ $406.46	$31.86B	0.57	1.76 million shs	967,907 shs
INTC Intel	$22.71 -3.9%	$22.33	$18.51 ▼ $45.41	$98.33B	1.02	74.65 million shs	58.18 million shs
JNJ Johnson & Johnson	$163.63 +0.3%	$158.68	$140.68 ▼ $169.99	$394.32B	0.47	7.63 million shs	5.76 million shs
PFE Pfizer	$25.20 +0.8%	$26.06	$24.48 ▼ $31.54	$142.93B	0.61	39.04 million shs	32.32 million shs
UNH UnitedHealth Group	$515.47 0.0%	$508.81	$436.38 ▼ $630.73	$471.51B	0.62	4.27 million shs	2.38 million shs
VHT Vanguard Health Care ETF	$262.90 -0.5%	$268.12	$250.07 ▼ $289.14	$22.94B	0.71	200,258 shs	256,298 shs
XLV Health Care Select Sector SPDR Fund	$144.52 -0.3%	$146.33	$135.95 ▼ $159.64	$38.15B	0.68	7.51 million shs	6.21 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GILD Gilead Sciences	0.00%	+4.40%	-2.20%	+21.50%	+52.61%
HUM Humana	0.00%	-0.89%	-2.57%	+3.81%	-23.87%
INTC Intel	0.00%	-6.39%	-4.34%	+14.58%	-48.59%
JNJ Johnson & Johnson	0.00%	+0.14%	-0.97%	+14.16%	+3.44%
PFE Pfizer	0.00%	-3.83%	-4.65%	-4.61%	-9.19%
UNH UnitedHealth Group	0.00%	-0.43%	+8.53%	+1.51%	+4.20%
VHT Vanguard Health Care ETF	0.00%	-1.51%	-3.29%	+3.84%	-2.82%
XLV Health Care Select Sector SPDR Fund	0.00%	-1.42%	-2.96%	+5.30%	-2.17%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GILD Gilead Sciences	4.5801 of 5 stars	2.4	4.0	1.7	4.1	3.5	2.5	1.9
HUM Humana	4.2254 of 5 stars	2.1	5.0	2.5	3.9	3.5	2.5	0.0
INTC Intel	3.9226 of 5 stars	3.0	3.0	0.0	2.4	3.3	1.7	1.3
JNJ Johnson & Johnson	4.4011 of 5 stars	2.3	3.0	4.2	3.9	3.5	2.5	0.6
PFE Pfizer	4.9865 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1
UNH UnitedHealth Group	4.9115 of 5 stars	3.5	3.0	4.2	4.0	3.5	3.3	1.3
VHT Vanguard Health Care ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GILD Gilead Sciences	2.72	Moderate Buy	$105.12	-5.97% Downside
HUM Humana	2.23	Hold	$285.68	8.24% Upside
INTC Intel	1.94	Reduce	$27.04	19.07% Upside
JNJ Johnson & Johnson	2.56	Moderate Buy	$171.33	4.71% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	26.67% Upside
UNH UnitedHealth Group	3.10	Buy	$629.32	22.09% Upside
VHT Vanguard Health Care ETF	2.76	Moderate Buy	$262.90	N/A
XLV Health Care Select Sector SPDR Fund	2.76	Moderate Buy	$144.52	N/A

Current Analyst Ratings Breakdown

Latest GILD, XLV, HUM, INTC, JNJ, PFE, UNH, and VHT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/27/2025	GILD Gilead Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$120.00 ➝ $130.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/13/2025	INTC Intel	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$19.00 ➝ $25.00
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/11/2025	GILD Gilead Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$123.00 ➝ $130.00
3/10/2025	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/5/2025	GILD Gilead Sciences	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$116.00 ➝ $126.00
3/5/2025	GILD Gilead Sciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$120.00 ➝ $140.00
3/5/2025	JNJ Johnson & Johnson	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$159.00 ➝ $171.00
3/4/2025	GILD Gilead Sciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$115.00 ➝ $132.00

(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GILD Gilead Sciences	$28.75B	4.84	$8.83 per share	12.66	$15.44 per share	7.24
HUM Humana	$117.76B	0.27	$23.21 per share	11.37	$136.57 per share	1.93
INTC Intel	$53.10B	1.85	$1.55 per share	14.65	$24.26 per share	0.94
JNJ Johnson & Johnson	$88.82B	4.44	$13.45 per share	12.17	$29.69 per share	5.51
PFE Pfizer	$63.63B	2.25	$3.95 per share	6.38	$15.81 per share	1.59
UNH UnitedHealth Group	$400.28B	1.18	$33.21 per share	15.52	$106.78 per share	4.83
VHT Vanguard Health Care ETF	N/A	N/A	N/A	N/A	N/A	N/A
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GILD Gilead Sciences	$480M	$0.37	302.14	13.78	0.71	1.67%	31.63%	10.38%	4/24/2025 (Estimated)
HUM Humana	$1.21B	$9.95	26.53	20.10	2.05	1.02%	11.70%	3.99%	4/23/2025 (Estimated)
INTC Intel	-$18.76B	-$4.38	N/A	40.55	N/A	-35.32%	-3.27%	-1.83%	4/24/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$6.65	24.61	14.78	2.56	18.20%	34.24%	13.63%	4/15/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.87	8.32	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
UNH UnitedHealth Group	$14.41B	$15.50	33.26	15.52	1.37	3.60%	26.69%	8.80%	4/17/2025 (Estimated)
VHT Vanguard Health Care ETF	N/A	N/A	29.75	∞	N/A	N/A	N/A	N/A	N/A
XLV Health Care Select Sector SPDR Fund	N/A	N/A	29.25	∞	N/A	N/A	N/A	N/A	N/A

Latest GILD, XLV, HUM, INTC, JNJ, PFE, UNH, and VHT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/24/2025	N/A	GILD Gilead Sciences	$1.73	N/A	N/A	N/A	$6.77 billion	N/A
4/24/2025	N/A	INTC Intel	$0.0017	N/A	N/A	N/A	$12.26 billion	N/A
4/23/2025	N/A	HUM Humana	$9.95	N/A	N/A	N/A	$32.00 billion	N/A
4/17/2025	N/A	UNH UnitedHealth Group	$7.24	N/A	N/A	N/A	$111.56 billion	N/A
4/15/2025	N/A	JNJ Johnson & Johnson	$2.59	N/A	N/A	N/A	$21.65 billion	N/A
2/11/2025	Q4 2024	GILD Gilead Sciences	$1.67	$1.90	+$0.23	$1.42	$7.15 billion	N/A
2/11/2025	Q4 2024	HUM Humana	-$2.26	-$2.16	+$0.10	-$5.76	$28.84 billion	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion
1/30/2025	Q4 2024	INTC Intel	$0.12	-$0.02	-$0.14	-$0.03	$13.83 billion	N/A
1/22/2025	Q4 2024	JNJ Johnson & Johnson	$1.99	$2.04	+$0.05	$1.41	$22.44 billion	$22.52 billion
1/16/2025	Q4 24	UNH UnitedHealth Group	$6.74	$6.81	+$0.07	$5.98	$101.60 billion	$100.81 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GILD Gilead Sciences	$3.16	2.83%	+2.74%	854.05%	N/A
HUM Humana	$3.54	1.34%	+8.13%	35.58%	N/A
INTC Intel	$0.50	2.20%	-28.88%	N/A	N/A
JNJ Johnson & Johnson	$4.96	3.03%	+5.43%	74.59%	63 Years
PFE Pfizer	$1.72	6.83%	+2.50%	121.99%	16 Years
UNH UnitedHealth Group	$8.40	1.63%	+13.46%	54.19%	15 Years
VHT Vanguard Health Care ETF	$3.87	1.47%	N/A	N/A	N/A
XLV Health Care Select Sector SPDR Fund	$2.29	1.58%	N/A	N/A	N/A

Latest GILD, XLV, HUM, INTC, JNJ, PFE, UNH, and VHT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/20/2025	HUM Humana	quarterly	$0.8850	1.33%	3/28/2025	3/28/2025	4/25/2025
2/5/2025	GILD Gilead Sciences	quarterly	$0.79	3%	3/14/2025	3/14/2025	3/28/2025
1/16/2025	VHT Vanguard Health Care ETF		$0.9396		3/25/2025	3/25/2025	3/27/2025
1/9/2025	XLV Health Care Select Sector SPDR Fund		$0.5645		3/24/2025	3/24/2025	3/26/2025
1/9/2025	XLV Health Care Select Sector SPDR Fund		$0.5645		3/24/2025	3/24/2025	3/26/2025
2/24/2025	UNH UnitedHealth Group	quarterly	$2.10	1.8%	3/10/2025	3/10/2025	3/18/2025
1/2/2025	JNJ Johnson & Johnson	quarterly	$1.24	3.43%	2/18/2025	2/18/2025	3/4/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GILD Gilead Sciences	1.24	1.50	1.20
HUM Humana	0.68	1.76	1.76
INTC Intel	0.44	1.33	0.98
JNJ Johnson & Johnson	0.43	1.11	0.86
PFE Pfizer	0.63	1.00	0.73
UNH UnitedHealth Group	0.74	0.83	0.91
VHT Vanguard Health Care ETF	N/A	N/A	N/A
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GILD Gilead Sciences	83.67%
HUM Humana	92.38%
INTC Intel	64.53%
JNJ Johnson & Johnson	69.55%
PFE Pfizer	68.36%
UNH UnitedHealth Group	87.86%
VHT Vanguard Health Care ETF	N/A
XLV Health Care Select Sector SPDR Fund	N/A

Insider Ownership

Company	Insider Ownership
GILD Gilead Sciences	0.16%
HUM Humana	0.37%
INTC Intel	0.04%
JNJ Johnson & Johnson	0.16%
PFE Pfizer	0.06%
UNH UnitedHealth Group	0.33%
VHT Vanguard Health Care ETF	N/A
XLV Health Care Select Sector SPDR Fund	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GILD Gilead Sciences	17,000	1.25 billion	1.24 billion	Optionable
HUM Humana	67,100	120.69 million	120.03 million	Optionable
INTC Intel	108,900	4.33 billion	4.33 billion	Optionable
JNJ Johnson & Johnson	152,700	2.41 billion	2.40 billion	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
UNH UnitedHealth Group	400,000	914.71 million	917.25 million	Optionable
VHT Vanguard Health Care ETF	N/A	87.27 million	N/A	Not Optionable
XLV Health Care Select Sector SPDR Fund	N/A	263.97 million	N/A	Not Optionable

GILD, XLV, HUM, INTC, JNJ, PFE, UNH, and VHT Headlines

Recent News About These Companies

Waters Corporation Stock: Is WAT Outperforming the Healthcare Sector?

March 26, 2025 | msn.com

Health Care Select Sector SPDR Fund (NYSEARCA:XLV) Stock Price Passes Below Two Hundred Day Moving Average - Time to Sell?

March 26, 2025 | americanbankingnews.com

S&P sector rankings as the first quarter of 2025's close is around the corner

March 24, 2025 | msn.com

3 Sector ETFs & Stocks to Gain Despite Downbeat February Jobs Data

March 14, 2025 | zacks.com

Merck and 8 More Healthcare Stocks for Nervous Dividend Investors

March 13, 2025 | msn.com

Select Sector SPDR ETFs: Strategic Investment with Sector-Specific Allocations

March 12, 2025 | finance.yahoo.com

Recession Fears Looming? Secure Your Portfolio With These ETFs

March 11, 2025 | zacks.com

Health Care Sector Trying to Bounce Back

March 6, 2025 | theglobeandmail.com

Shifting Tides in Leadership: Markets Play Defense

March 6, 2025 | etftrends.com

Time for Defensive Sector ETFs?

February 27, 2025 | zacks.com

Healthcare best performing sector as market angst builds

February 25, 2025 | marketwatch.com

Healthcare Stocks Should Be Hurting. How the Sector Became This Year’s Top Performer.

February 25, 2025 | msn.com

Health Care Has Been a Top Sector

February 22, 2025 | finance.yahoo.com

What Top-Performing Healthcare Funds Are Buying Now

February 19, 2025 | msn.com

Final Trade: FWONK, XLV, MSFT, PEP

February 13, 2025 | youtube.com

18 out of 21 healthcare companies beat profit estimates this week- Earnings scorecard

February 8, 2025 | msn.com

Financials, Health Care Sectors Leading U.S. Stocks Higher In 2025

February 7, 2025 | seekingalpha.com

Stock Market Rotation: To Healthcare (XLV), Then Biotechnology (IBB)

February 6, 2025 | seeitmarket.com

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

February 4, 2025 | zacks.com

Can Health Care ETFs Aid Your Portfolio?

February 3, 2025 | etftrends.com

S&P 500 Earnings Set to Shine: January's Critical Market Test (XLV)

December 27, 2024 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
Intel Foundry’s Moment of Truth: Will 18A Deliver?
By Jeffrey Neal Johnson | March 6, 2025
View Intel Foundry’s Moment of Truth: Will 18A Deliver?
Intel's Strategy to Win the Next AI Frontier
By Jeffrey Neal Johnson | March 27, 2025
View Intel's Strategy to Win the Next AI Frontier
Resilient Investing: 3 Stocks Built to Weather Market Volatility
By Jeffrey Neal Johnson | March 17, 2025
View Resilient Investing: 3 Stocks Built to Weather Market Volatility
Intel Stock Rallies on Leadership Change—Time to Buy or Wait?
By Jeffrey Neal Johnson | March 20, 2025
View Intel Stock Rallies on Leadership Change—Time to Buy or Wait?

GILD, XLV, HUM, INTC, JNJ, PFE, UNH, and VHT Company Descriptions

Gilead Sciences NASDAQ:GILD

$111.79 +0.63 (+0.57%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$111.55 -0.24 (-0.21%)

As of 03/28/2025 07:58 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Humana NYSE:HUM

$263.95 -6.43 (-2.38%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$262.75 -1.20 (-0.45%)

As of 03/28/2025 07:55 PM Eastern

Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Intel NASDAQ:INTC

$22.71 -0.91 (-3.85%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$22.62 -0.09 (-0.40%)

As of 03/28/2025 07:59 PM Eastern

Intel Corporation designs, develops, manufactures, markets, and sells computing and related products and services worldwide. It operates through Client Computing Group, Data Center and AI, Network and Edge, Mobileye, and Intel Foundry Services segments. The company's products portfolio comprises central processing units and chipsets, system-on-chips (SoCs), and multichip packages; mobile and desktop processors; hardware products comprising graphics processing units (GPUs), domain-specific accelerators, and field programmable gate arrays (FPGAs); and memory and storage, connectivity and networking, and other semiconductor products. It also offers silicon devices and software products; and optimization solutions for workloads, such as AI, cryptography, security, storage, networking, and leverages various features supporting diverse compute environments. In addition, the company develops and deploys advanced driver assistance systems (ADAS), and autonomous driving technologies and solutions; and provides advanced process technologies backed by an ecosystem of IP, EDA, and design services, as well as systems of chips, including advanced packaging technologies, software and accelerate bring-up, and integration of chips and driving standards. Further, it delivers and deploys intelligent edge platforms that allow developers to achieve agility and drive automation using AI for efficient operations with data integrity, as well as provides hardware and software platforms, tools, and ecosystem partnerships for digital transformation from the cloud to edge. The company serves original equipment manufacturers, original design manufacturers, cloud service providers, and other manufacturers and service providers. It has a strategic agreement with Synopsys, Inc. to develop EDA and IP solutions; and ARM that enables chip designers to build optimized compute SoCs on the Intel 18A process. Intel Corporation was incorporated in 1968 and is headquartered in Santa Clara, California.

Johnson & Johnson NYSE:JNJ

$163.63 +0.50 (+0.31%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$163.36 -0.27 (-0.17%)

As of 03/28/2025 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Pfizer NYSE:PFE

$25.20 +0.19 (+0.76%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$25.14 -0.07 (-0.26%)

As of 03/28/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

UnitedHealth Group NYSE:UNH

$515.47 -0.25 (-0.05%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$514.75 -0.72 (-0.14%)

As of 03/28/2025 07:59 PM Eastern

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

Vanguard Health Care ETF NYSEARCA:VHT

$262.90 -1.25 (-0.47%)

Closing price 03/28/2025 04:10 PM Eastern

Extended Trading

$262.74 -0.16 (-0.06%)

As of 03/28/2025 07:33 PM Eastern

Vanguard Health Care ETF seeks to track the investment performance of the MSCI US Investable Market Health Care 25/50 Index, a benchmark of large-, mid-, and small-cap United States stocks in the health care sector, as classified under the Global Industry Classification Standard (GICS). This GICS sector is made up of two main industry groups. The first group includes companies that manufacture health care equipment and supplies or provide health care related services (such as distributors of health care products, providers of basic health care services, and owners and operators of health care facilities and organizations). The second group includes companies primarily involved in the research, development, production, and marketing of pharmaceuticals and biotechnology products. The Vanguard Group, Inc., through its Quantitative Equity Group, serves as the investment advisor of the Fund.

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$144.52 -0.45 (-0.31%)

Closing price 03/28/2025 04:10 PM Eastern

Extended Trading

$144.31 -0.21 (-0.15%)

As of 03/28/2025 07:56 PM Eastern

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GILD, XLV, HUM, INTC, JNJ, PFE, UNH, and VHT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GILD, XLV, HUM, INTC, JNJ, PFE, UNH, and VHT Earnings

Compare Dividends

Latest GILD, XLV, HUM, INTC, JNJ, PFE, UNH, and VHT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GILD, XLV, HUM, INTC, JNJ, PFE, UNH, and VHT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GILD, XLV, HUM, INTC, JNJ, PFE, UNH, and VHT Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools